Abstract
Purpose: This study was undertaken to examine the feasibility of combining radiolabeled antibody therapy with high-dose chemotherapy followed by autologous bone marrow transplantation in patients with poorprognosis Hodgkin's disease. Patients and Methods: Patients were entered onto this protocol if they had chemotherapy-resistant disease, bulky disease, or extensive prior therapy. Patients received yttrium-labeled antif erritin on day -13, -12, or - 11, followed by high-dose cyclophosphamide, carmustine, and etoposide (CBV) on days -6 to -3, and then bone marrow infusion on day 0. Results: Twelve patients received both radiolabeled antibody and high-dose chemotherapy followed by autologous transplantation. Two additional patients started the study, but were unable to complete all therapy. Four of 12 patients experienced early transplant-related mortality. Four patients are alive more than 2 years following transplantation and three are free from disease progression at 24 +, 25 +, and 28 + months following transplantation. The progression-free survival rate at 1 year is estimated to be 21%. Considering the poor prognostic characteristics of these patients, toxicity on this protocol was not necessarily greater than that observed with high-dose chemotherapy alone. Conclusion: This report demonstrates the feasibility of combining radiolabeled antibody therapy with highdose chemotherapy and autologous bone marrow transplantation.
Original language | English (US) |
---|---|
Pages (from-to) | 698-703 |
Number of pages | 6 |
Journal | Journal of Clinical Oncology |
Volume | 11 |
Issue number | 4 |
State | Published - 1993 |
ASJC Scopus subject areas
- Oncology
- Cancer Research